Amgen Eschews Some Of Its BiTEs, But Otezla Spurs Growth

Pipeline Changes Planned As Data Evolved

 
• By Mandy Jackson

Without Otezla’s $2.2bn in 2020 sales, Amgen’s full-year revenue would have been slightly lower than in 2019, which is why all eyes are on the company’s R&D programs and near-term approvals.

Top view of calculator,keyboard,pen and notebook written with Fourth Quarter.
Amgen's 2020 revenue of $25.4bn was in line with consensus expectations • Source: Shutterstock

More from Earnings

More from Business